Inotiv, Inc. (NOTV) Stock
NOTV Key Statistics
About Inotiv, Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
CEO: Robert W. Leasure Jr.. Company website
NOTV — Frequently Asked Questions
What is the NOTV stock price today?
Inotiv, Inc. (NOTV) trades at $0.08, down 26.28% on the day, as of Sep 20, 2026 14:59 UTC.
What is Inotiv, Inc.'s market cap?
Inotiv, Inc. has a market capitalisation of $2.82M, calculated from the live NOTV share price and shares outstanding.
What is the P/E ratio of NOTV?
NOTV has no meaningful price-to-earnings ratio: Inotiv, Inc. lost $2.03 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Inotiv, Inc. make?
Inotiv, Inc. generated revenue of $514.03M over the trailing twelve months, which puts the stock at 0.01 times sales.
What is the 52-week range for NOTV?
NOTV has traded between $0.08 and $0.48 over the past 52 weeks, and the last price is 83.1% below that high.
Is Inotiv, Inc. profitable?
No. Inotiv, Inc. is loss-making, with a net margin of -13.50% over the trailing twelve months.
What is the analyst price target for NOTV?
Wall Street analysts rate NOTV Buy, with an average price target of $3.00, 3,563.0% above the current price.
What sector is Inotiv, Inc. in?
Inotiv, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US .
Who is the CEO of Inotiv, Inc.?
Robert W. Leasure Jr. is the chief executive of Inotiv, Inc., which employs 1,977 people.
Where can I track NOTV in real time?
QFI Terminal shows NOTV with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See NOTV live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open NOTV in Terminal See plans